title: Scleroderma--developing measures of response.
abstract: The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.
authors.affiliation: University of California at Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst
authors.forename: Dinesh
authors.initials: D
authors.lastname: Khanna
authors.forename: Marco
authors.initials: M
authors.lastname: Mattucci-Cerinic
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Silman
authors.forename: Peter A
authors.initials: PA
authors.lastname: Merkel
authors.forename: Ivan
authors.initials: I
authors.lastname: Foeldvari
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005385:Fingers; D005767:Gastrointestinal Diseases / Q000209:etiology; D005919:Glomerular Filtration Rate; D006304:Health Status; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D012107:Research Design; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000473:pathology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012883:Skin Ulcer / Q000209:etiology / Q000473:pathology